Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02315924
Other study ID # COCCAICOCA
Secondary ID
Status Recruiting
Phase N/A
First received December 2, 2014
Last updated July 19, 2016
Start date March 2013
Est. completion date December 2016

Study information

Verified date July 2016
Source Capital Medical University
Contact Qiang Fu, MD, Ph.D
Phone 861067096562
Email fuqiang66882000@hotmail.com
Is FDA regulated No
Health authority China: Ministry of Health
Study type Interventional

Clinical Trial Summary

Intracranial atherosclerosis is common vascular lesion in Asian acute stroke patients and intracranial atherosclerosis patients have high rate of coronary artery disease (CAD). Moreover, several studies showed obvious association of CAD and cerebrovascular stenosis, which had been proved to increase the risk of stroke after coronary revascularization including coronary bypass surgery or percutaneous coronary intervention. In addition, the efficacy and safety of combined coronary and cerebral intervention are not fully investigated. Hence, the aim of this study is to evaluate the prevalence and characteristics of coronary and cerebrovascular arteriosclerosis as measured by combined coronary and cerebral angiography, explore the relationship between inflammation, atherosclerosis-related markers and coronary and cerebral atherosclerosis and compare the efficacy and safety of simultaneous or staged coronary and cerebral interventional strategy in Chinese Patients.

The coronary angiography and cerebrovascular angiography are performed for all participants. The combined strategy for coronary and cerebrovascular angiography is carried out routinely in the investigators institutions. Simultaneous strategy is considered as that performed via the same access and within the same day. Staged strategy is intended as that performed within 7 days from the first procedure. The sequence of angiographies is established on an individual patient basis by the cardiovascular and neurointerventional team according to clinical symptoms of the patients and after coronary or cerebrovascular angiography. After combined coronary and cerebral angiography, simultaneous or staged interventional strategy will be performed in patients with severe coronary and cerebral stenosis. Blood sample is obtained from artery sheath when performing coronary or cerebral angiography. Lipid levels, inflammation and atherosclerosis-related markers will be measured in this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

1. Age 20-80 years old;

2. Patients with clinical indication for coronary angiography;

3. Patients with suspected cerebrovascular atherosclerosis;

4. Written informed consent.

Exclusion Criteria:

1. Patients who have symptomatic congestive heart failure (New York Heart Association Class III or IV)

2. Patients who develop acute myocardial infarction

3. The presence of severe liver disease including chronic active hepatitis, or chronic jaundice with hyperbilirubinemia

4. Patients with renal dysfunction, or with nephrotic syndrome

5. Patients with cancer

6. Unable or unwilling to comply with protocol requirements, or deemed by the investigator to be unfit for the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
simultaneous coronary and cerebral intervention
Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
staged coronary and cerebral intervention
Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.

Locations

Country Name City State
China Beijing Tiantan Hospital, Capital Medical University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other inflammation marker myeloperoxidase, lipoprotein-associated phospholipase A2, oxidized low density lipoprotein, C-reaction protein, F2-isoprostane, leptin, adiponectin. 2 years No
Primary stroke 1 year Yes
Primary acute myocardial infarction 1 year Yes
Secondary extracranial arterial stenosis North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria were used for extracranial carotid stenosis calculations.The degree of extracranial carotid stenosis and stenosis in the extracranial segment of the vertebral artery was classified as normal, <50%, 50-69%, 70-89%, and 90-99% stenosis, or occluded. We defined angiographic extracranial arterial stenosis as a diameter stenosis of >70% on the common carotid artery, the carotid bifurcation, the internal carotid artery, and vertebral artery. 2 years No
Secondary intracranial arterial stenosis Intracranial stenoses were measured according to the methods described in the Warfarin-Aspirin for Symptomatic Intracranial Disease Study. The degree of stenosis in the intracranial segment of the internal carotid artery, stenosis in the intracranial segment of the vertebral artery, and stenosis in the basilar artery were classified as normal or =25%, 25-49%, =50% stenosis and occlusion. We defined angiographic intracranial cerebral artery stenosis as a diameter stenosis of >50% on the intracranial segment of the internal carotid artery and the vertebral artery, and the basilar artery. Stenoses were classified as moderate (50-69%) or severe (70-99%). 2 years No
Secondary coronary stenosis severity The modified Gensini's stenosis scoring system was used to assess the severity of coronary lesions. The Gensini score was calculated by assigning a severity score to each coronary stenosis according to the degree of luminal narrowing and its geographic importance. Severity scores assigned to the specific percentage luminal diameter reduction of the coronary artery segment were 32 for 100%, 16 for 99%, 8 for 75%, 2 for 50%, and 1 for 25%. 2 years No
Secondary coronary stenosis extent According to the number of diseased vessels, all patients were classified into: no vessel disease (VD); 1-VD; 2-VD; 3-VD; left main trunk disease. 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT03427996 - Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Terminated NCT03175523 - HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Completed NCT01184183 - Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
Completed NCT00697372 - SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Phase 4
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Recruiting NCT03054324 - Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
Enrolling by invitation NCT06194526 - Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Not yet recruiting NCT05753085 - Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment N/A
Not yet recruiting NCT05471687 - Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT N/A
Not yet recruiting NCT04569669 - The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis N/A
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A
Completed NCT03301246 - Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease N/A
Completed NCT03606330 - Systemic, Pancoronary and Local Coronary Vulnerability
Completed NCT02870140 - Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent N/A
Not yet recruiting NCT06071702 - IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System N/A
Completed NCT02275143 - Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis N/A
Active, not recruiting NCT01794065 - The Promus Element Rewards Study N/A